Of the multiple small-scaleclinical trials using PPARγ ligands for cancer treatment, only two showedpromising results: in an early study TGZ caused prolonged PSA stabilization inprostate cancer patients [84], while PGZ combined withlow-dose chemotherapy and rofexoxib produced moderate improvement in thepatients with high-grade glioma [85]. Here, PPARG is linked to cancer.